Steminent Biotherapeutics Inc is a Taiwan-based trading company mainly engaged in the research and development of new stem cell drugs and the development of allogeneic mesenchymal stem cell technology platforms. The Company's main product is the new stem cell drug product Stemchymal. The new stem cell drug product Stemchymal is used to treat spinocerebellar ataxia, Huntington's disease, acute ischemic stroke, acute inflammatory indications and other diseases.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-07-05	NT$74.00	+0.41%	93,355
26-07-03	NT$73.70	-0.67%	76,726
26-07-02	NT$74.20	-2.50%	103,845
26-07-01	NT$76.10	-2.31%	112,734
26-06-30	NT$77.90	+0.78%	116,441

End-of-day quote Taipei Exchange

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Taipei Exchange Other stock markets 2026-07-06			5-day change	1st Jan Change
74.00 ^TWD	+0.41%		-4.39%	+23.13%

03-31	Steminent Biotherapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-18	Steminent Biotherapeutics Inc. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI

Market Cap	4.93B 154M 135M 124M 115M 219M 14.67B 222M 1.49B 578M 7.2B 578M 565M 24.97B	P/E 2024	-8.1x	P/E 2025	-20.4x
Enterprise Value	4.51B 141M 123M 113M 105M 200M 13.41B 203M 1.36B 528M 6.58B 528M 516M 22.82B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	65.1%	Yield 2024 *	-	Yield 2025	-

03-31	Steminent Biotherapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-18	Steminent Biotherapeutics Inc. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-04-24	Steminent Biotherapeutics Inc. to Showcase Breakthrough MSC-Based Therapy for Spinocerebellar Ataxia at WODC USA and ISCT 2025	CI

1 day	+0.41%
1 week	-4.39%
Current month	-5.01%
1 month	-2.12%
3 months	-5.01%
6 months	+25.64%
Current year	+23.13%

Steminent Biotherapeutics Inc. Stock

Stocks

7729

TW0007729006

Biotechnology & Medical Research

Valuation: Steminent Biotherapeutics Inc.

Chart: Steminent Biotherapeutics Inc.

Latest news : Steminent Biotherapeutics Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Steminent Biotherapeutics Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	72.2	80.9
1 month	72.2	91
Current year	51.4	95.6
1 year	20.65	95.6
3 years	15.25	95.6
5 years	15.25	95.6
10 years	15.25	95.6

Manager	Title	Age	Since
Ling Mei Wang CEO	Chief Executive Officer	-	2018-11-25
I Chih Lo DFI	Director of Finance/CFO	-	2021-09-14
Ching Huai Ko IRC	Investor Relations Contact	-	2023-09-30

Director	Title	Age	Since
Hai Yi Ma BRD	Director/Board Member	-	2024-01-25
Chih Hung Yeh BRD	Director/Board Member	54	2021-12-07
Kung-Wha Ding BRD	Director/Board Member	72	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
STEMINENT BIOTHERAPEUTICS INC.	+0.41%	-4.39%	+256.63%	-	154M
LONZA GROUP AG	+1.08%	+8.57%	+3.61%	+9.34%	49.92B
REVOLUTION MEDICINES, INC.	+0.40%	-1.37%	+418.11%	+625.15%	40.23B
IQVIA HOLDINGS INC.	-0.52%	+6.57%	+26.79%	-5.37%	34.55B
BEONE MEDICINES AG	+3.97%	+6.71%	+28.41%	+63.36%	33.09B
CELLTRION, INC.	-4.19%	+6.03%	+3.76%	+32.17%	27.51B
ASCENDIS PHARMA A/S	-2.40%	+1.60%	-	-	17.05B
MEDPACE HOLDINGS, INC.	+1.34%	+5.68%	+77.20%	+141.51%	15.92B
EUROFINS SCIENTIFIC SE	-0.95%	-0.38%	+12.92%	+17.96%	13.86B
IONIS PHARMACEUTICALS, INC.	+1.69%	+3.09%	+99.09%	+99.19%	13.52B
Average	+0.02%	+4.65%	+102.95%	+122.91%	24.58B
Weighted average by Cap.	+0.10%	+6.42%	+95.11%	+141.10%

	2024	2025
Net sales	-	-
Net income	-159M -4.95M -4.34M -4M -3.71M -7.04M -472M -7.14M -47.82M -18.61M -232M -18.6M -18.19M -804M	-174M -5.43M -4.76M -4.38M -4.07M -7.72M -518M -7.82M -52.43M -20.4M -254M -20.39M -19.94M -881M
Net Debt	-153M -4.78M -4.19M -3.86M -3.58M -6.8M -456M -6.89M -46.16M -17.96M -224M -17.95M -17.56M -776M	-426M -13.29M -11.64M -10.72M -9.95M -18.89M -1.27B -19.15M -128M -49.92M -622M -49.89M -48.8M -2.16B